Department of Cardiology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.
Department of Cardiology, Affiliated Zhongshan Hospital, Dalian University, Dalian, 116001, China.
Lipids Health Dis. 2018 Jun 30;17(1):151. doi: 10.1186/s12944-018-0801-x.
Intestinal microflora has been shown to play essential roles in the clinical therapies of metabolic diseases. The present study is aiming to investigate the potential roles and mechanisms of how intestinal microflora mediates lipid-reduction efficacy of Rosuvastatin.
To investigate the correlation between the intestinal microflora and efficacy of Rosuvastatin, we analyzed the diversity of intestinal microflora using PCR-DGGE analysis and 16S rDNA sequencing approaches. Furthermore, we compared the blood lipid levels of rat models with dysbiosis of intestinal microflora and control rats upon the Rosuvastatin administration.
The diversity of the intestinal flora was obviously decreased upon the antibiotic treatment, this effect could be maintained for 2 weeks after establishment of the models. Importantly, the results from 16S rDNA sequencing demonstrated that the abundance of Lactobacillus and Bifidobacterium was remarkably diminished upon the antibiotic treatment in antibiotic+Rosuvastatin-treated group compared to that of Rosuvastatin-treated group and control group. Correspondently, the lipid-reduction efficacy of Rosuvastatin was significantly compromised. However, the diversity of the intestinal flora was recovered 4 weeks after the antibiotic treatment. Subsequently, the lipid-reduction efficacy of Rosuvastatin was also recovered to level of the control rats treated with Rosuvastatin alone.
Intestinal flora could play an essential role in mediating the lipid-reduction efficacy of Rosuvastatin.
肠道微生物群已被证明在代谢疾病的临床治疗中发挥着重要作用。本研究旨在探讨肠道微生物群如何介导瑞舒伐他汀降脂疗效的潜在作用和机制。
为了研究肠道微生物群与瑞舒伐他汀疗效之间的相关性，我们使用 PCR-DGGE 分析和 16S rDNA 测序方法分析了肠道微生物群的多样性。此外，我们比较了肠道微生物群失调的大鼠模型和给予瑞舒伐他汀的对照大鼠的血脂水平。
抗生素治疗后，肠道菌群的多样性明显降低，这种影响在模型建立后可持续 2 周。重要的是，16S rDNA 测序结果表明，与瑞舒伐他汀治疗组和对照组相比，抗生素+瑞舒伐他汀治疗组中乳酸杆菌和双歧杆菌的丰度明显降低。相应地，瑞舒伐他汀的降脂效果明显受损。然而，抗生素治疗 4 周后，肠道菌群的多样性得到恢复。随后，瑞舒伐他汀的降脂效果也恢复到单独给予瑞舒伐他汀的对照组大鼠的水平。
肠道菌群在介导瑞舒伐他汀的降脂疗效中起着重要作用。
